Takeda and Amylin terminate $1 billion anti-obesity pact

Decision follows agreement in August 2011 to discontinue the development of pramlintide/metreleptin

Jeffrey Bouley
DEERFIELD, Ill.—Takeda Pharmaceutical Co. Ltd.today announced that it has mutually terminated its worldwideagreement with Amylin Pharmaceuticals Inc., originally signed inOctober 2009, to co-develop and commercialize compounds for obesity.
The companies announced in August 2011their decision specifically to discontinue the development ofpramlintide/metreleptin, an investigational combination therapy forthe treatment of obesity. That joint decision was based on acommercial reassessment of the pramlintide/metreleptin program, whichhad been in Phase II development as a twice-a-day injectionformulation.
The companies have since determined to formallyterminate the obesity partnership at this time. According to Takeda, "Having greatly benefited fromthe Amylin team's collective experience and scientific expertise,Takeda will continue to enhance its R&D activities in the area ofobesity as well as its other core therapeutic areas to meet the needsof patients."

Takeda's consolidated financialstatement for the fiscal 2012 will not be impacted by the terminationof this partnership.

SOURCE: Takeda news release

Jeffrey Bouley

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

February 2023 Front Cover

Latest Issue  

• Volume 19 • Issue 2 • February 2023

February 2023

February 2023 Issue